Idiopathic pulmonary fibrosis represents a high need specialty market, with global IPF drug sales of roughly USD 3 billion ...

The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...

Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...

Dern, whose mother, Actress Diane Ladd, died of PF in November, shared about her caregiver experience on television ...

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

Evaluating quality of life (QOL) in patients with idiopathic pulmonary fibrosis (IPF) goes beyond lung function numbers. It also shows how treatments affect daily well-being and guides funding, ...

PHILADELPHIA (WPVI) -- There's another disease to add to the list of smoking-related ailments. But for doctors, they are still learning about CPFE or Combined Pulmonary Fibrosis and Emphysema. For ...

Breathing in microplastics can cause inflammation and damage to the lungs, potentially increasing the risk of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype, ...

Dr. Shune concludes the discussion by focusing on safety, sequencing, and practical considerations for incorporating axatilimab into the cGVHD treatment paradigm. She notes that d ...

To date, the molecular basis of pulmonary fibrosis has been poorly understood. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now shown that reduced activity ...